SCM
APLS

Suvretta Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Suvretta Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142M Sell
3,518,471
-620,955
-15% -$13.4M 3.62% 5
2025
Q4 		$104M Buy
4,139,426
+1,261,426
+44% +$29.6M 2.13% 11
2025
Q3 		$65.1M Hold
2,878,000
– – 1.67% 19
2025
Q2 		$49.8M Buy
2,878,000
+1,231,385
+75% +$22.8M 1.5% 24
2025
Q1 		$36M Buy
1,646,615
+853,428
+108% +$23.6M 1.34% 24
2024
Q4 		$25.3M Buy
+793,187
New +$23.9M 0.86% 39
2020
Q2 		– Sell
-21,600
Closed -$579K – 81
2020
Q1 		$579K Buy
+21,600
New +$767K 0.02% 60

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Suvretta Capital Management's APLS Position: Q1 2026 in Review

Suvretta Capital Management reduced its Apellis Pharmaceuticals (APLS) stake by 15% in Q1 2026, selling an estimated $13.4M and leaving 3,518,471 shares worth $142M. The position accounts for 3.62% of the portfolio, ranked #5.

Suvretta Capital Management first reported a position in APLS in Q1 2020 and has held it in 7 quarters since. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Suvretta Capital Management held 3,518,471 shares of Apellis Pharmaceuticals worth $142M as of Q1 2026.
  • Suvretta Capital Management sold 620,955 Apellis Pharmaceuticals shares in Q1 2026, an estimated $13.4M.
  • Apellis Pharmaceuticals made up 3.62% of Suvretta Capital Management's portfolio in Q1 2026, its #5 holding.
  • Suvretta Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2020 and has held it in 7 quarters since.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Suvretta Capital Management's 13F filing for Q1 2026, filed 15 May 2026.